Abstract: A flow control valve includes a membrane which has at least one opening for the flow of a fluid and an annular body which has a flow contact surface and at least one flow opening. The flow opening is in flow connection with the at least one opening in the membrane. The membrane is constructed to be bendable in a direction towards the flow contact surface.

Abstract: A jet regulator for fluids includes a housing wall and a deflecting device arranged at least partially within the housing wall. The deflecting device deflects a centrally inflowing fluid oppositely to its inlet direction. The deflecting device and the housing wall define a flow path.

Abstract: A flow control valve includes a membrane which has at least one opening for the flow of a fluid and an annular body which has a flow contact surface and at least one flow opening. The flow opening is in flow connection with the at least one opening in the membrane. The membrane is constructed to be bendable in a direction towards the flow contact surface.

Abstract: Compounds corresponding to formula I, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and n have the meanings given in the description, and also a process for the preparation of these compounds and intermediate products of this process. Furthermore, pharmaceutical compositions comprising the compounds of Formula I and related methods of treatment.

Abstract: A novel combination therapy for cardiovascular diseases or conditions, including administering a synergistic combination of at least one inhibitor of neutral endopeptidase, at least one inhibitor of the endogenous endothelin producing system and at least one diuretic, preferably a thiazide diuretic or an adenosine A1 antagonist.

Abstract: A combination therapy is disclosed for treating or inhibiting cardiovascular or metabolic diseases or conditions through a combination of at least one inhibitor of neutral endopeptidase (=NEP), at least one inhibitor of the endogenous endothelin producing system and at least one HMG CoA reductase inhibitor. Pharmaceutical compositions are also described comprising NEP inhibitors, inhibitors of the endogenous endothelin producing system and HMG CoA reductase inhibitors and the use of these pharmaceutical composition in the prophylaxis or treatment of cardiovascular and/or metabolic disorders or diseases in mammals (including humans).

Abstract: A combination therapy for cardiovascular diseases, in particular essential hypertension, pulmonary hypertension and/or congestive heart failure, involving administering a synergistic combination of at least one inhibitor of neutral endopeptidase, at least one inhibitor of the endogenous endothelin producing system, and at least one AT1 receptor antagonist.

Abstract: Compounds corresponding to formula I, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and n have the meanings given in the description, and also a process for the preparation of these compounds and intermediate products of this process. Furthermore, pharmaceutical compositions comprising the compounds of Formula I and related methods of treatment.

Abstract: Compounds corresponding to formula I, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and n have the meanings given in the description, and also a process for the preparation of these compounds and intermediate products of this process. Furthermore, pharmaceutical compositions comprising the compounds of Formula I and related methods of treatment.

Abstract: The use of compounds corresponding to formula I: in which R1, R2, R3, R4, R5 and R6 have the meanings given in the description for treating cardiac arrhythmias and other disease states.

Abstract: The use of compounds corresponding to formula I: in which R1, R2, R3, R4, R5 and R6 have the meanings given in the description for treating cardiac arrhythmias and other disease states.

Abstract: Compounds corresponding to formula I: in which R1, R2, R3, R4, R5 and R6 have the meanings given in the description; a process for the preparation of these compounds; intermediate products used to prepare such compounds, and pharmaceutical compositions containing such compounds.

Abstract: Described herein are pharmaceutical combinations comprising a therapeutically effective amount of a first selective adenosine A1 antagonist and a first radiocontrast media. A kit comprising a therapeutically effective amount of the combination of a first selective adenosine A1 antagonist and a first radiocontrast media is also described herein.

Abstract: Described herein are pharmaceutical combinations comprising a therapeutically effective amount of a first selective adenosine A1 antagonist and a first radiocontrast media. In one embodiment the selective adenosine A1 antagonist comprises 4-[(2-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-trans-cyclohexanol methanesulfonate and/or (4S)-4-hydroxy-1-(2-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-L-prolinamide methanesulfonate. Also described are the use of a first selective adenosine A1 antagonist in the treatment of radiocontrast media induced nephropathy. Furthermore, a kit comprising a therapeutically effective amount of a first selective adenosine A1 antagonist and a first radiocontrast media is also described herein.

Abstract: Novel compounds corresponding to formula I, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and n have the meanings given in the description, and also a process for the preparation of these compounds and intermediate products of this process. Furthermore, pharmaceutical compositions comprising the compounds of Formula I and related methods of treatment.

Abstract: A novel combination therapy for cardiovascular diseases or conditions, including administering a synergistic combination of at least one inhibitor of neutral endopeptidase, at least one inhibitor of the endogenous endothelin producing system and at least one diuretic, preferably a thiazide diuretic or an adenosine A1 antagonist.

Abstract: A combination therapy is disclosed for treating or inhibiting cardiovascular or metabolic diseases or conditions through a combination of at least one inhibitor of neutral endopeptidase (=NEP), at least one inhibitor of the endogenous endothelin producing system and at least one HMG CoA reductase inhibitor. Pharmaceutical compositions are also described comprising NEP inhibitors, inhibitors of the endogenous endothelin producing system and HMG CoA reductase inhibitors and the use of these pharmaceutical composition in the prophylaxis or treatment of cardiovascular and/or metabolic disorders or diseases in mammals (including humans).

Abstract: A combination therapy for cardiovascular diseases, in particular essential hypertension, pulmonary hypertension and/or congestive heart failure, involving administering a synergistic combination of at least one inhibitor of neutral endopeptidase, at least one inhibitor of the endogenous endothelin producing system, and at least one AT1 receptor antagonist.

Abstract: A combination therapy for the inhibition and/or treatment of sexual dysfunction and/or cardiovascular diseases in humans and other mammals, by administering a synergistic combination of at least one inhibitor of neutral endopeptidase, at least one inhibitor of the endogenous endothelin producing system, and at least one inhibitor of phosphodiesterase 5.

Abstract: The present invention relates to the novel medicinal use of dually acting compounds capable of inhibiting neutral endopeptidase (=NEP) and human soluble endopeptidase (=hSEP) in the prophylaxis and/or treatment of sexual dysfunction in mammals and humans.